BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
ACA subsidies latest: Making sense of what's happening with health care after Republicans revolt, forcing a vote on funding extension - 2This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- 3Why is the Artemis 2 rocket launch different from all other rocket launches?
- 4The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- 5The Force of Positive Reasoning: Day to day Attestations
- Germany expresses 'great concern' over Israel's new death penalty law
- Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- There are thousands of aligned holes in Peru. Archaeologists now think they know who made them
- First part of major new German-Danish tunnel cleared for lowering
- Top 15 Supportable Design Brands Coming out on top
- Toyota Reports 2.3% Sales Drop as China Weakness Deepens
- Los Angeles County sees significant uptick in norovirus cases, officials say
- The Ascent of the Kona SUV: How Hyundai's Reduced Hybrid Is Vanquishing the Streets
- Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
